SpringWorks Therapeutics
100 Washington Blvd
Stamford
Connecticut
06902
United States
Website: http://www.springworkstx.com/
Email: Media@springworkstx.com
110 articles with SpringWorks Therapeutics
-
SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022
5/16/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it will host a virtual R&D Day for investors and analysts on Friday, June 10, 2022 at 10:00 am ET.
-
SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/5/2022
SpringWorks Therapeutics, Inc reported first quarter financial results for the period ended March 31, 2022 and provided an update on recent company developments.
-
SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma
4/19/2022
SpringWorks Therapeutics, Inc. announced that the company has entered into a clinical trial collaboration and supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with Regeneron’s investigational bispecific antibody targeting B-cell maturation antigen and CD3, REGN5458, in patients with relapsed or refractory multiple myeloma.
-
Regeneron Augments I-O Portfolio with Checkmate, Partners with SpringWorks on Multiple Myeloma
4/19/2022
Regeneron announced it has acquired Checkmate Pharmaceuticals and that it has entered a clinical trial collaboration with SpringWorks Therapeutics to treat multiple myeloma. -
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
2/24/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported financial results for the fourth quarter and full-year periods ended December 31, 2021 and provided an update on recent company developments.
-
SpringWorks Therapeutics to Present at Upcoming Investor Conferences - Feb 01, 2022
2/1/2022
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that management will present at the following upcoming investor conferences:
-
SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 am ET.
-
SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma
12/10/2021
SpringWorks Therapeutics, Inc. today announced that the company has entered into a clinical trial collaboration agreement with AbbVie, Inc. to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor.
-
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma
12/6/2021
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that the first patient has been dosed in a Phase 1b/2 trial evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor (GSI), in combination with elranatamab (PF-06863135) Pfizer’s investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas
11/29/2021
SpringWorks Therapeutics, Inc. today announced that it has achieved full enrollment in its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with NF1-associated plexiform neurofibromas (NF1-PN).
-
SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
11/23/2021
SpringWorks Therapeutics, Inc. today announced that management will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, November 30, 2021, at 3:30 pm ET.
-
SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
11/4/2021
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported financial results for the third quarter and year-to-date periods ended September 30, 2021 and provided an update on recent company developments.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors
10/20/2021
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into an exclusive worldwide license agreement with Dana-Farber Cancer Institute (Dana-Farber) and a sponsored research agreement (SRA) with Stanford Medicine for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor (EGFR) designed for the treatment of EGFR-mutant lung cancers.
-
SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics
10/20/2021
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into a collaboration agreement with Ab Magnitude Ventures Group, LLC and Ab Magnitude Fund, LP (collectively, “Ab Magnitude”) for the development of next-generation targeted oncology therapeutics.
-
SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference.
-
SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
8/30/2021
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that it has entered into a sponsored research collaboration with Dana-Farber Cancer Institute.
-
SpringWorks has announced a research collaboration with the Dana-Farber Cancer Institute to advance its therapy development efforts for multiple myeloma and related diseases.
-
Clinical Catch-Up: August 2-6
8/9/2021
It was a busy week for clinical trial announcements. Take a look.